In favor of its use as a clinical therapeutic target, GPRC5D has many advantages: it is almost exclusively restricted to cancer cells, with only low expression detected in normal tissues [30], it has BCMA-independent expression on plasma cells, which ensures persistence of expression even in relapse after therapy against BCMA [32], and it has shown excellent preclinical results in vivo in terms of efficacy and safety, independent of prior BCMA-targeted therapy and also including activity in a BCMA antigen escape model [33]. This evidence concerns the gene TNFRSF17 and cancer.